心血管

订阅

MedSci主页 / 所有栏目 / 心血管

SCI REP：癌症患者组织因子结合MPs与静脉血栓形成风险之间的相关性分析！

2018-01-27 xing.T MedSci原创

TF-MPs静脉血栓形成风险相关性
关注

总之，TF-MPs与癌症患者静脉血栓栓塞的风险增加有关。然而，需要更精心设计的研究以及对混杂因素进行更全面的调整来证实这种相关性。

癌症患者组织因子（TF）结合微粒（TF-MPs）被发现与静脉血栓栓塞风险增加有关，但这些研究结果并不一致。近日，Scientific reports杂志上发表了一篇荟萃分析文章，研究人员的目的是评估TF-MPs与癌症患者静脉血栓栓塞风险之间的相关性。

研究人员检索了PubMed、Web of Science和EMBASE数据库，检索时间截止至2017年6月1日。在这项分析中，两项病例对照研究和四项队列研究符合分析的要求。研究人员采用随机效应模型估计了总的比值比。

研究人员发现总的比值比为1.76（95%可信区间为1.21-2.56，I2=62%）。病例对照研究的比值比为3.41（95%可信区间为1.45-8.02，I2=0%），队列研究的比值比为1.53（95%可信区间为1.05-2.24，I2=66.1%）。该荟萃分析发现携带的MPs与癌症患者静脉血栓栓塞的风险之间存在关联。发表偏倚检测和敏感性亚组分析表明该荟萃分析的结果是稳健的。

总之，TF-MPs与癌症患者静脉血栓栓塞的风险增加有关。然而，需要更精心设计的研究以及对混杂因素进行更全面的调整来证实这种相关性。

原始出处：

Chan-juan Cui,et al. Tissue Factor-bearing MPs and the risk of venous thrombosis in cancer patients: A meta-analysis.Scientific reports.2018. https://www.nature.com/articles/s41598-018-19889-8

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697628, encodeId=1851169e628df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 09 04:10:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664388, encodeId=46b81664388cd, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Thu Dec 20 17:10:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955341, encodeId=d31c1955341f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Oct 09 23:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837444, encodeId=d004183e444f3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 16 20:10:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984950, encodeId=0c5c19849503f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Apr 01 13:10:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285846, encodeId=21032858466c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Feb 07 07:13:47 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284134, encodeId=d3d1284134f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 01 09:54:01 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289580, encodeId=0f7b128958042, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483263, encodeId=f12f148326386, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523591, encodeId=6ded1523591a2, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=)]
    2018-07-09 fusion

    #静脉#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1697628, encodeId=1851169e628df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 09 04:10:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664388, encodeId=46b81664388cd, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Thu Dec 20 17:10:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955341, encodeId=d31c1955341f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Oct 09 23:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837444, encodeId=d004183e444f3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 16 20:10:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984950, encodeId=0c5c19849503f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Apr 01 13:10:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285846, encodeId=21032858466c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Feb 07 07:13:47 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284134, encodeId=d3d1284134f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 01 09:54:01 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289580, encodeId=0f7b128958042, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483263, encodeId=f12f148326386, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523591, encodeId=6ded1523591a2, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=)]
    2018-12-20 12498bf3m33暂无昵称

    #组织因子#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1697628, encodeId=1851169e628df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 09 04:10:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664388, encodeId=46b81664388cd, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Thu Dec 20 17:10:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955341, encodeId=d31c1955341f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Oct 09 23:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837444, encodeId=d004183e444f3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 16 20:10:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984950, encodeId=0c5c19849503f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Apr 01 13:10:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285846, encodeId=21032858466c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Feb 07 07:13:47 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284134, encodeId=d3d1284134f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 01 09:54:01 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289580, encodeId=0f7b128958042, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483263, encodeId=f12f148326386, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523591, encodeId=6ded1523591a2, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=)]
    2018-10-09 xue8602

    #静脉血#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1697628, encodeId=1851169e628df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 09 04:10:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664388, encodeId=46b81664388cd, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Thu Dec 20 17:10:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955341, encodeId=d31c1955341f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Oct 09 23:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837444, encodeId=d004183e444f3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 16 20:10:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984950, encodeId=0c5c19849503f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Apr 01 13:10:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285846, encodeId=21032858466c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Feb 07 07:13:47 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284134, encodeId=d3d1284134f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 01 09:54:01 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289580, encodeId=0f7b128958042, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483263, encodeId=f12f148326386, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523591, encodeId=6ded1523591a2, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=)]
    2018-12-16 shenxlcyp

    #相关性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1697628, encodeId=1851169e628df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 09 04:10:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664388, encodeId=46b81664388cd, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Thu Dec 20 17:10:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955341, encodeId=d31c1955341f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Oct 09 23:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837444, encodeId=d004183e444f3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 16 20:10:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984950, encodeId=0c5c19849503f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Apr 01 13:10:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285846, encodeId=21032858466c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Feb 07 07:13:47 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284134, encodeId=d3d1284134f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 01 09:54:01 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289580, encodeId=0f7b128958042, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483263, encodeId=f12f148326386, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523591, encodeId=6ded1523591a2, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=)]
    2018-04-01 124987e8m07暂无昵称

    #MPS#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1697628, encodeId=1851169e628df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 09 04:10:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664388, encodeId=46b81664388cd, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Thu Dec 20 17:10:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955341, encodeId=d31c1955341f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Oct 09 23:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837444, encodeId=d004183e444f3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 16 20:10:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984950, encodeId=0c5c19849503f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Apr 01 13:10:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285846, encodeId=21032858466c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Feb 07 07:13:47 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284134, encodeId=d3d1284134f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 01 09:54:01 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289580, encodeId=0f7b128958042, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483263, encodeId=f12f148326386, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523591, encodeId=6ded1523591a2, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=)]
    2018-02-07 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1697628, encodeId=1851169e628df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 09 04:10:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664388, encodeId=46b81664388cd, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Thu Dec 20 17:10:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955341, encodeId=d31c1955341f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Oct 09 23:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837444, encodeId=d004183e444f3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 16 20:10:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984950, encodeId=0c5c19849503f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Apr 01 13:10:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285846, encodeId=21032858466c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Feb 07 07:13:47 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284134, encodeId=d3d1284134f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 01 09:54:01 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289580, encodeId=0f7b128958042, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483263, encodeId=f12f148326386, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523591, encodeId=6ded1523591a2, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=)]
    2018-02-01 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1697628, encodeId=1851169e628df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 09 04:10:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664388, encodeId=46b81664388cd, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Thu Dec 20 17:10:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955341, encodeId=d31c1955341f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Oct 09 23:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837444, encodeId=d004183e444f3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 16 20:10:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984950, encodeId=0c5c19849503f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Apr 01 13:10:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285846, encodeId=21032858466c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Feb 07 07:13:47 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284134, encodeId=d3d1284134f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 01 09:54:01 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289580, encodeId=0f7b128958042, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483263, encodeId=f12f148326386, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523591, encodeId=6ded1523591a2, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=)]
    2018-01-29 zgwhgch

    #癌症患者#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1697628, encodeId=1851169e628df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 09 04:10:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664388, encodeId=46b81664388cd, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Thu Dec 20 17:10:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955341, encodeId=d31c1955341f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Oct 09 23:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837444, encodeId=d004183e444f3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 16 20:10:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984950, encodeId=0c5c19849503f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Apr 01 13:10:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285846, encodeId=21032858466c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Feb 07 07:13:47 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284134, encodeId=d3d1284134f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 01 09:54:01 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289580, encodeId=0f7b128958042, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483263, encodeId=f12f148326386, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523591, encodeId=6ded1523591a2, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=)]
    2018-01-29 ms5187542471278033

    #静脉血栓形成#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1697628, encodeId=1851169e628df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 09 04:10:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664388, encodeId=46b81664388cd, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Thu Dec 20 17:10:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955341, encodeId=d31c1955341f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Oct 09 23:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837444, encodeId=d004183e444f3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 16 20:10:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984950, encodeId=0c5c19849503f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sun Apr 01 13:10:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285846, encodeId=21032858466c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Feb 07 07:13:47 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284134, encodeId=d3d1284134f1, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Feb 01 09:54:01 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289580, encodeId=0f7b128958042, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483263, encodeId=f12f148326386, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523591, encodeId=6ded1523591a2, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Jan 29 02:10:00 CST 2018, time=2018-01-29, status=1, ipAttribution=)]
    2018-01-29 anminleiryan

    #相关性分析#

    0

以上为热门评论，梅斯医学App还有更多内容